(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/109133 A1

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61K 38/22* (2006.01)
A61K 38/20 (2006.01) *C12N 15/86* (2006.01)

(21) International Application Number:
PCT/US2021/059887

(22) International Filing Date:
18 November 2021 (18.11.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/116,004 19 November 2020 (19.11.2020) US

(71) Applicant: **KALIVIR IMMUNOTHERAPEUTICS, INC.** [US/US]; 240 Alpha Drive, Pittsburgh, Pennsylvania 15238 (US).

(72) Inventors: **THORNE, Stephen Howard**; 610 Whispering Pines Drive, Pittsburgh, Pennsylvania 15238 (US). **ZHANG, Mingrui**; 6251 Broad Street, #112, Pittsburgh, Pennsylvania 15206 (US). **BYRD, Daniel J.**; 12000 Park Plaza Drive, Apt. 202, Pittsburgh, Pennsylvania 15229 (US).

(74) Agent: **HENDRICKS, Diana G.** et al.; c/o Greenberg Traurig, LLP, One International Place, Suite 2000, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICRO-ENVIRONMENT REMODELING




FIG. 1

(57) Abstract: The disclosure relates to modified oncolytic viruses. The modified oncolytic viruses of the disclosure comprise modification in the viral genome encoding exogenous nucleic acids to enhance the oncolytic immunotherapy by remodeling the tumor microenvironment and with enhanced systemic delivery. The disclosure further relates to compositions comprising the modified oncolytic viruses, kits containing the same, and methods of using the oncolytic viruses.

WO 2022/109133 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*